Cellular Intelligence acquires global rights to STEM-PD program
WHY IT MATTERS
This acquisition signals renewed investment in stem cell therapy for Parkinson's disease, potentially accelerating development of a treatment option that could help patients with progressive motor symptoms who have limited disease-modifying therapies available.
A company called Cellular Intelligence has bought the rights to develop a new Parkinson's disease treatment from another company called Novo Nordisk. The treatment uses stem cells (special cells that can become different types of cells) from donors. Cellular Intelligence will use artificial intelligence technology to help develop and manufacture this therapy, and Novo Nordisk is investing money in the company to support this work.
Cellular Intelligence has acquired global rights from Novo Nordisk to STEM-PD, an allogeneic, or donor-derived, stem cell therapy program for Parkinson’s disease. Under the terms of the agreement, Cellular Intelligence will apply its artificial intelligence (AI) platform to advance the clinical development and manufacturing of the cell therapy, while Novo Nordisk becomes an equity investor […] The post Cellular Intelligence acquires global rights to STEM-PD program appeared first on Parkin